The c-Myb and v-Myb proteins are transcription factors that regulate cell proliferation and dierentiation. Both Myb proteins have been shown to interact with a number of cellular proteins, some of which are transcription factors that cooperate to activate speci®c promoters, while others regulate the transcriptional activity of Myb in speci®c contexts. By comparing and analysing the types of proteins that bind Myb, and the conserved domains of Myb that interact with other proteins, conclusions can be drawn regarding the role of speci®c partner proteins in the regulation of gene expression, cell proliferation and disease.
The speci®c regulation of a single eukaryotic gene requires a molecular machine involving the cooperation of dozens, perhaps hundreds of dierent proteins (for reviews see Armstrong and Emerson, 1998; Kadonaga, 1998) . Given the complexity of such interactions, it is remarkable that individual transcription factors, such as c-Myb, can profoundly in¯uence the expression of speci®c genes (for a discussion of Myb-regulated genes, see . In addition, since hundreds of transcription factors have been identi®ed in eukaryotic cells, it is surprising that so few have the capacity to function as transforming proteins. Thus, c-Myb belongs to an elite class of oncogenic transcription factors capable of controlling dierentiation and proliferation. There is no doubt that the dramatic activity of c-Myb is determined by its functional domains ( Figure 1 ). The c-Myb protein has a highly conserved DNA binding domain near its N-terminus, a central trans-activation domain and a C-terminal negative regulatory domain, the latter of which is deleted in the activated v-Myb form (for review see . The functional domains are highly conserved among c-Myb proteins from various species, and confer the ability to bind speci®c DNA sequences and partner proteins. Recently, a variety of proteins have been identi®ed which can interact with cMyb or v-Myb. Some of these have been shown to alter the activity or speci®city of the Myb proteins, suggesting that they play important roles in transformation or the regulation of cell growth or differentiation.
This review will discuss the cellular factors that have been shown to interact with Myb proteins. The focus will be on the vertebrate proteins related to cMyb, which are the only ones that have been shown to regulate cell growth and which are likely to play a role in tumorigenesis. Although a number of transcription factors can cooperate with Myb to regulate speci®c promoters, this discussion will be limited to proteins that have been shown to bind directly to Myb proteins.
Proteins that bind c-Myb or v-Myb
The c-Myb protein is expressed in nearly all immature, proliferating hematopoietic precursors as well as several other cell types including some dierentiating epithelia. It probably functions in a combinatorial manner with other transcription factors to induce appropriate genes in speci®c lineages (for review see Ness and Engel, 1994) . Thus, c-Myb regulates lineagespeci®c genes although its expression is not lineage speci®c. Several transcription factors, such as Ets-12 (Dudek et al., 1992) , CBF/PEBP2/AML1 (HernandezMunain and Krangel, 1994, 1995; Zaiman and Lenz, 1996) and BZLF1 (Kenney et al., 1992) , can cooperate with c-Myb to activate speci®c enhancers or promoters. These proteins appear to cooperate without speci®cally binding to Myb, and the ability of c-Myb to cooperate with so many dierent transcription factors may be important for its role in controlling dierentiation.
However, a variety of transcription factors, coactivators, regulatory proteins and enzymes have been shown to bind directly to c-Myb or B-Myb proteins (Table 1) and can be divided into several classes. First, some DNA-binding transcription factors can bind directly to c-Myb. Second, several types of transcriptional coactivators, that are thought to mediate interactions with the transcriptional machinery, can bind Myb proteins. Finally, some proteins bind Myb and alter its activity, and appear to play a direct regulatory role. Each of these types of proteins can be either an activator or repressor of c-Myb or v-Myb function.
Activators of Myb
One transcription factor has been shown to both cooperate with c-Myb and to bind directly to it in vivo. C/EBPb (also known as NF-IL6 and NF-M) cooperates with c-Myb and v-Myb in the activation of speci®c genes, such as mim-1 (Burk et al., 1993; Ness et al., 1993) . The Myb and C/EBPb proteins bind to adjacent sites on the mim-1 promoter, and both proteins are required to induce ecient expression of the mim-1 gene. In addition, the v-Myb and C/EBPb proteins have been shown to interact using several independent in vitro assays, and the proteins can be co-immunoprecipitated from extracts of at least one vMyb-transformed myeloblast cell line (Mink et al., 1996) . The DNA binding domains of v-Myb and C/ EBPb appear to mediate the interaction between the two proteins, providing evidence that these conserved domains do more than recognize particular binding sites in promoters.
As an oncoprotein with the capacity to induce cell proliferation, appropriate regulation of c-Myb activity in normal cells is crucial to preventing inappropriate cell growth. Thus, some of the most interesting Mybbinding proteins are those which aect its transcriptional activity. In particular, these proteins may provide a link between c-Myb or v-Myb activity in the nucleus, and signal transduction pathways originating in the cytoplasm. To date, two dierent types of transcriptional coactivators have been shown to interact with v-Myb and c-Myb proteins, and both have important implications for the regulation of Myb protein activity in transformation and tumorigenesis.
CBP and p300
CBP or CREB-Binding Protein and its close relative p300 are ubiquitous coactivators that interact with a variety of transcription factors as well as numerous transforming proteins (Arany et al., 1994) . CBP and p300 have histone acetyltransferase activity (Ogryzko et al., 1996) and are presumed to play a role in chromatin remodeling (for reviews see Armstrong and Emerson, 1998; Kadonaga, 1996) . However, they have also been shown to acetylate transcription factors such as p53 (Gu and Roeder, 1997; Sakaguchi et al., 1998) and may be able to directly modify Myb proteins as well.
CBP was ®rst identi®ed as a regulated coactivator of the transcription factor CREB, and binds the latter protein in a phosphorylation-dependent manner (Arias et al., 1994; Chrivia et al., 1993) . Although Myb and CREB bind the same domain of CBP (Dai et al., 1996; Kiewitz and Wolfes, 1997; OelgeschlaÈ ger et al., 1996) , the interaction with Myb proteins is constitutive rather than phosphorylation-dependent (Dai et al., 1996; OelgeschlaÈ ger et al., 1996) . Interestingly, CBP and p300 can also interact with and stimulate the activity of C/EBPb (Mink et al., 1997; OelgeschlaÈ ger et al., 1996) , suggesting that the coactivators may act as a bridge between Myb and C/EBPb (Figure 1 ). This type of bridging activity could explain the ability of Myb proteins to cooperate with C/EBPb and a wide variety of other transcription factors, in the context of dierent promoters. CBP and p300 bind the transactivation domains of c-Myb and C/EBPb, located in their central and N-terminal domains, respectively (Dai et al., 1996; Kietwitz and Wolfes, 1997; Mink et al., 1997; OelgeschlaÈ ger et al., 1996) . This suggests that the coactivators are involved in mediating the transactivation activity of Myb and C/EBPb.
Several results indicate that CBP or p300 are required for c-Myb or v-Myb transcriptional activity. For example, c-Myb-regulated promoters are inhibited by expression of anti-sense CBP mRNA (Dai et al., 1996) or dominant-negative mutants of CBP (OelgeschlaÈ ger et al., 1996) . In addition, viral transforming proteins such as the adenovirus protein E1A, that bind to and inactivate CBP and p300, can interfere with Myb-dependent transcription (Dai et al., 1996; OelgeschlaÈ ger et al., 1996) . Finally, the HTLV protein Tax1, which can inhibit c-Myb protein activity in Tcells, apparently does so by binding to and sequestering the available CBP/p300 proteins (Colgin and Nyborg, 1998) . This raises the intriguing possibility that inhibition of c-Myb transcriptional activity may be necessary for E1A-or Tax1-mediated transformation of some cell types. The c-Myb and v-Myb proteins have also been shown to interact with p100, a second type of transcriptional coactivator unrelated to CBP/p300 (Dash et al., 1996) . The p100 protein was ®rst identi®ed as a coactivator of the Epstein-Barr virus nuclear protein EBNA2 (Tong et al., 1995) , a transcription factor involved in EBVmediated B-cell transformation. The p100 protein is ubiquitously expressed, and can interact with the general transcription factor TFIIE in vitro. However, in most cells the protein is predominantly cytoplasmic (SA Ness, unpublished), suggesting that its subcellular localization may be regulated by upstream signaling pathways.
The interest in p100 as a coactivator for c-Myb was originally sparked by an unusual structural feature. The protein contains a region that is highly related to the EVES domain, a portion of the c-Myb negative regulatory domain which can mediate intramolecular interactions with the Myb DNA binding domain (Dash et al., 1996) . Based on its sequence similarity to c-Myb, p100 was tested in several types of binding assays, and was shown to interact with c-Myb and v-Myb proteins both in vitro and in vivo (Dash et al., 1996) . Dominant negative versions of p100 were able to block the expression of Myb-dependent promoters (Dash et al., 1996; , indicating that p100 played a role in mediating the transcriptional activity of c-Myb and v-Myb. In addition, the fact that p100 contained an EVES domain like the one in the c-Myb negative regulatory domain suggested a novel form of regulation. Speci®cally, intramolecular interactions between the two ends of c-Myb could regulate the intermolecular interactions between p100 and Myb. This concept will be discussed in more detail later.
The identi®cation of p100 as a Myb-binding protein also provided links to cytoplasmic signaling cascades. Besides interacting with EBNA2 and Myb, p100 was also identi®ed in a yeast two-hybrid screen as a protein that interacted with the serine/threonine protein kinase Pim-1 . The Pim-1 kinase is encoded by an oncogene that can operate with activated alleles of c-myc to induce murine lymphoid tumors (van Lohuizen et al., 1989) . Pim-1 is expressed in immature hematopoietic cells, the same cells that express c-Myb (for review see Ihle et al., 1990) , and its expression is regulated by STAT-factor mediated signaling cascades downstream of hematopoietic cytokine receptors (Miura et al., 1994) . For these reasons, Pim-1 is precisely the type of protein kinase that one would expect to regulate c-Myb activity. Indeed, ectopic expression of Pim-1 in hematopoietic cells stimulated the transcriptional activity of Myb proteins, but this eect was shown to be p100-dependent . Dominant-negative mutants of p100 were able to block the Pim-1 eect, and Pim-1 was unable to stimulate c-Myb or v-Myb activity in mutant cells lacking p100 . Thus, Pim-1 and p100 appear to be components of a novel signal transduction cascade, downstream of hematopoietic cytokine receptors, that regulates the activity of Myb proteins.
Inhibitors of Myb
The c-Myb protein is expressed in immature, proliferating cells and overexpression of v-Myb or c-Myb can induce immature phenotypes in some dierentiated cells Ness et al., 1987 Ness et al., , 1993 . This suggests that c-Myb function must be inactivated during the dierentiation of normal hematopoietic cells. Interestingly, two transcription factors that induce dierentiation have direct negative eects on c-Myb.
RARa and c-Maf
Retinoic acid induces the dierentiation of many hematopoietic cell types by activating speci®c nuclear receptors, such as RARa, a transcription factor that can bind speci®c sites in DNA and regulate gene expression. Dominant-negative versions of RARa can block the dierentiation of hematopoietic cell lines in tissue culture and in vivo. For example, myeloid (Ying et al., 1997) leukemias result from the transforming potential of the dominant-negative Pml-RARa fusion protein (for reviews see Chen et al., 1996; Grignani et al., 1993) . Thus, the eect of RARa is opposite to that of cMyb, and recent evidence suggests that expression of RARa may inhibit the activity of c-Myb and v-Myb in hematopoietic cells (P®tzner et al., 1998) . Ectopic expression of RARa can inhibit the transcriptional activity of an estrogen-regulated v-Myb-ER fusion protein in a macrophage-like cell line, when measured using a reporter gene derived from a Myb-regulated gene (P®tzner et al., 1998) . In addition, retinoic acid treatment can block v-Myb-dependent gene activation under some conditions. These results are complicated by the fact that retinoic acid treatment or expression of RARa could aect Myb proteins indirectly, perhaps by inducing dierentiation changes that in turn aect the expression of other proteins. Nevertheless, bacterially-expressed Myb and RARa proteins can interact in vitro, suggesting that RARa is able to directly aect the activity of v-Myb and c-Myb (P®tzner et al., 1998) .
Like RARa, c-Maf plays a role in promoting dierentiation. The c-Maf protein is a bZip transcription factor related to MafB, an avian protein which can bind to and inhibit the activity of Ets proteins (Sieweke et al., 1997) . Recently, c-Maf has been shown to interact with both Ets and Myb proteins and to inhibit their collaborative activation of the CD13/APN gene promoter in immature myelolid cells (Hegde et al., 1998) . Since c-Maf expression increases during differentiation, this provides a mechanism for repression of CD13/APN, which is activated by Myb plus Ets only in immature cells. As a bZip protein, c-Maf is related to C/EBPb (NF-M), which cooperates with Myb and Ets proteins to activate the mim-1 promoter. In addition, both c-Maf and C/EBPb appear to interact with the DNA binding domain of c-Myb (see below). This suggests that the two types of bZip proteins may have opposing roles in the regulation of myeloid cell dierentiation (Burk et al., 1993; Hegde et al., 1998; Ness et al., 1993) .
p160/p67
Several proteins that can inhibit c-Myb activity are not DNA-binding transcription factors, and work through other mechanisms. The c-Myb protein contains a leucine-rich domain that is C-terminal of the transactivation domain and retained in AMV v-Myb (see Figure 2) , and which has been termed the leucine zipper (LZ) region (Kanei-Ishii et al., 1992; Ramsay et al., 1991) . Mutation of the LZ domain can stimulate cMyb transcriptional activity, suggesting that it plays a role in negative regulation. Although the LZ region can mediate Myb-Myb dimer formation under some conditions in vitro (Nomura et al., 1993) , there is no evidence that such multimers exist in vivo. Indeed, the LZ region of c-Myb is quite unlike other proteins with leucine zipper dimerization domains, such as c-Fos, cJun, c-Myc or C/EBPb, which are obligated to form dimers in order to bind DNA. Instead, the c-Myb LZ behaves like a protein interaction domain, rather than a dimer-forming leucine zipper region.
Recently, a cellular protein capable of binding the cMyb LZ region was identi®ed (Tavner et al., 1998) . The p160 protein contains a bona ®de leucine zipper that can form dimers with c-Jun, and a separate region that binds the c-Myb LZ domain. Cell extracts contain p160 as well as p67, an N-terminal proteolytic fragment of p160. Both p160 and p67 contain the Myb-binding domain. Overexpression of the p67 protein can inhibit the transactivation activity of wild type c-Myb. However, mutation of the LZ domain prevents binding by p67, and renders Myb resistant to the inhibitory eects of p67. Thus, these results demonstrate conclusively that the c-Myb LZ domain is indeed a protein binding domain, although it may not be a leucine zipper in the classic sense. In addition, p160/p67 appears to be an important regulator of cMyb activity, which can be aected by mutations in LZ. Surprisingly, p160 is localized predominantly in the nucleolus, at least in ®broblasts. This implies that c-Myb may have a regulatory role in nucleolar function, or that a fraction of p160/p67 remains outside the nucleolus to participate in regulation of cMyb. It will also be interesting to ®nd out if the proteolysis of p160 (to generate p67) is a regulated event, and whether that could play a role in the subcellular localization of this interesting inhibitor of cMyb.
c-Myb, v-Myb and cyclins
Since c-Myb and v-Myb are oncoproteins and control proliferation, they are expected to have some link to the cell cycle regulatory machinery. For example, the Myb-related protein B-Myb has S phase speci®c transactivation activity, and is regulated by cyclindependent kinases (Lane et al., 1997; Sala et al., 1997; Ziebold et al., 1997) . Ironically, B-Myb has not been shown to be oncogenic, and no evidence linking c-Myb activity to cell cycle regulation has been reported. Recently, however, the activity of v-Myb was shown to be inhibited by the G1-speci®c cyclins D1 and D2, that can interact directly with the v-Myb DNA binding domain (Ganter et al., 1998) . Ectopic expression of the G1 cyclins blocked the transactivation activity of vMyb, in a manner that was independent of cyclindependent kinases, suggesting that the eects were not linked to cell cycle control. The unexpected result was that the cyclins had no detectable eect on the activity of c-Myb. Indeed, truncation of the c-Myb DNA binding domain, which is required for full oncogenic activity, rendered the protein more susceptible to repression by cyclin D1 and D2 (Ganter et al., 1998) . This suggests that the oncogenic activity of v-Myb is linked to its ability to be repressed by cyclin D1 or D2, a result that seems somewhat counterintuitive. Fulllength and C-terminal truncated versions of c-Myb, which should not interact with cyclins D1 or D2, have transforming activity in some systems (Ferrao et al., 1995; Garrido et al., 1992; Gonda et al., 1989b) . Thus, Myb proteins that do not bind cyclins can still transform.
What is the role of cyclins in Myb protein regulation? It is possible that the repression results cited above were a consequence of the experimental system used, and that cyclins actually play a dierent role in vivo. Perhaps cyclins D1 and D2 act as novel transcription coactivators to modify v-Myb activity on speci®c promoters? Alternatively, the Myb proteins might in fact be modi®ers of cyclin activity. Indeed, a Myb-related protein named DMP1 has been identi®ed which can bind to and inhibit the cell cycle activities of cyclins D1 and D2 (Inoue and Sherr, 1998) . So far, interaction with cyclins has not been shown to be required for the transforming activity of v-Myb. However, the fact that cyclins can have speci®c effects on v-Myb activity is signi®cant and interesting, and may be the ®rst clue to role of c-Myb and v-Myb in cell cycle control.
Conformational changes and regulation of c-Myb activity
One of the most important features of an oncogenic transcription factor is its regulation, since changes in activity may equate to increased cell proliferation. In general, c-Myb seems to be regulated at the protein level, since it is relatively highly expressed in a constitutive fashion in immature cells. The c-Myb protein is regulated by several mechanisms. It will be necessary to understand these mechanisms to determine how mutations activate c-Myb in transformation and tumorigenesis.
Intramolecular interactions
The c-Myb protein has a well-characterized negative regulatory domain, and C-terminal truncation of cMyb, or the related A-Myb or B-Myb proteins, enhances transcriptional activity (Gonda et al., 1989a; GraÈ sser et al., 1991; Lane et al., 1997; Takahashi et al., 1995) . In addition, overexpression of c-Myb is insucient to eciently transform cells in vitro or to induce tumors in animals (for review see . This suggests that negative regulation of c-Myb is inherent to its structure, rather than being a function of a limiting cellular protein capable of binding to and inhibiting Myb activity.
Recently, the C-terminal negative regulatory region of c-Myb was shown to be able to interact with its Nterminal, DNA binding domain (Dash et al., 1996) . The original yeast two-hybrid and in vitro binding studies have since been con®rmed using phage display technology (Kiewitz and Wolfes, 1997) . These results support a hypothesis suggesting that c-Myb activity is regulated by intramolecular interactions and conformational changes. Thus, cis interactions between the two ends of c-Myb could in¯uence trans interactions with transcriptional coactivators, cooperating proteins or DNA . Intramolecular interactions in c-Myb are mediated by the EVES motif, a conserved element in the negative regulatory domain that overlaps a site of in vivo phosphorylation (Aziz et al., 1995) . Mutations in the EVES domain contribute to activation of c-Myb (Dubendor et al., 1992) and the c-Myb EVES domain has a counterpart in p100 (see above), which also binds the Myb DNA binding domain. A model for regulation of c-Myb activity, based on competition between the EVES domains of c-Myb and p100, is proposed in Figure 1 . As proposed, the c-Myb DNA binding domain is able to simultaneously interact with speci®c sites in the DNA as well as cooperating transcription factors such as C/EBPb or Ets-1, and an EVES domain-containing protein. The latter can be either p100 (or a complex of p100 plus Pim-1, as shown in Figure 1a) or the c-Myb negative regulatory domain (Figure 1b) . Binding of other proteins, such as CBP/ p300 or p160 (not shown), which interact with other domains of c-Myb, could also occur simultaneously (Figure 1) . Complexes containing c-Myb simultaneously interacting with DNA, CBP/p300 and other transcription factors or coactivators have not yet been identi®ed. Nor have interactions between Myb and EVES domain proteins been shown to aect c-Myb DNA binding. However, it is interesting to speculate that intramolecular interactions in c-Myb could mask binding sites for other proteins, such as CBP/p300, or interfere with DNA binding. Truncations or mutations in c-Myb, which alleviate intramolecular interactions, could activate c-Myb by increasing interactions with DNA or coactivators. In addition, the proposed model would provide a mechanism for speci®c activation of alternative sets of Myb-regulated genes. This type of mechanism would allow signal transduction through Pim-1 to aect the choice of target genes regulated by c-Myb.
The proposal outlined in Figure 1 is consistent with results and data from numerous laboratories, but is meant only as a working model and as a starting point for further analysis. Future experiments will have to address issues of target gene selection by Myb, mechanisms regulating DNA binding and protein interaction, and the dierences between wild type cMyb and activated transforming alleles. In particular, while the concept of intramolecular interactions between the c-Myb DNA binding and EVES domains is appealing, there is little information about how such interactions are regulated. Thus, it is crucial to determine how regulatory conformation changes in a c-Myb are controlled in vivo.
Conformational changes and DNA binding
Several types of evidence indicate that c-Myb DNA binding activity is negatively regulated. For example, C-terminal truncation can increase the DNA binding activity of c-Myb protein, suggesting that the negative regulatory domain plays an inhibitory role (Ramsay et al., 1991) . Similarly, full length c-Myb protein synthesized in insect cells has impaired DNA binding activity, which can be recovered by mild protease digestion to remove the negative regulatory domain (AB Dash, JD Leverson and SA Ness, unpublished) .
Recently, c-Myb DNA binding activity was shown to be regulated by Cyp40 (Leverson and Ness, 1998) , a cyclophilin with peptidyl-prolyl isomerase activity capable of altering protein conformations and catalyzing protein folding reactions (Kieer et al., 1993) . Cyp40 is comprised of a C-terminal protein binding domain containing tetratricopeptide (TPR) repeats, and an N-terminal catalytic domain which binds cyclosporin-A and has peptidyl-prolyl isomerase activity. The TPR repeats bind speci®cally to the DNA binding domain of c-Myb, allowing the catalytic domain to inhibit c-Myb DNA binding activity (Leverson and Ness, 1998) . Inhibition is blocked by cyclosporin-A, a competitive inhibitor of Cyp40 peptidyl-prolyl isomerase activity, requires both functional domains of Cyp40, and only works on c-Myb proteins containing an intact C-terminal regulatory domain (Leverson and Ness, 1998) .
Perhaps the most striking feature of Cyp40 regulation is that it is c-Myb speci®c. The DNA binding domain in the AMV form of v-Myb contains three point mutations which are predicted to lie on the solvent exposed surface of the protein (for review see . These mutations alter the biological properties of v-Myb and its ability to induce speci®c target genes (Introna et al., 1990; Kowenz-Leutz et al., 1997; Ness et al., 1989) , and contribute to the transforming potential of the oncoprotein (Dini et al., 1995) . The mutations also disrupt the Cyp40 binding site, and render v-Myb immune to the inhibitory eects of the cyclophilin (Leverson and Ness, 1998) . The results suggest that Cyp40 catalyzes conformational changes in c-Myb which aect its DNA binding activity (for review see Hunter, 1998) . In addition, vMyb appears to have acquired mutations that allow it to evade negative regulation by Cyp40, suggesting that point mutations can play a critical role in Myb protein activation.
Conserved functional domains in c-Myb
The c-Myb and v-Myb proteins have been shown to interact with numerous proteins, many of which can in¯uence transcriptional or transforming activity. When one analyses the structures of c-Myb proteins (Figure 2) , it becomes clear that the most conserved regions correspond to protein interaction domains. For example, the p160/p67 protein binds the LZ region (also known as FAETL) and CBP/p300 binds the transactivation domain (TAD). Most of the other proteins interact with the Myb DNA binding domain. Interestingly, the mutations in v-Myb are clustered in the same conserved, protein interaction domains. This suggests that v-Myb has speci®cally acquired mutations that in¯uence protein-protein interactions.
The Myb DBD as DNA/protein docking domain One of the most striking features of c-Myb, as shown in Figure 2 , is the fact that so many dierent proteins are able to interact with the DNA binding domains of Myb proteins. The minimal DNA binding domain, comprised of Myb repeats two and three (for review see , interacts with at least eight of the proteins discussed above. These include the bZip proteins c-Maf and C/EBPb, the G1 cyclins D1 and D2, the transcription factors RARa and HSF3, the coactivator p100 and the cyclophilin Cyp40. The domain also interacts intramolecularly with the cMyb EVES domain. There are undoubtedly additional partners that have not yet been described. Thus, this single, highly conserved domain of roughly 120 amino acids emerges as an intricate DNA/protein docking domain responsible for mediating a wide array of dierent interactions. There can be little doubt that the DNA binding domain is the`business end' of Myb, which explains why this portion of the protein is identical in species as divergent as chickens and humans. With this in mind, it is remarkable that any Myb proteins can accommodate mutations in the DNA binding domain.
Mutations in v-Myb target speci®c protein binding sites
Another conclusion that can be surmised from the comparisons outlined in Figure 2 concerns v-Myb. Of the 11 point mutations acquired by the transforming protein, nearly all cause alterations in important functional domains. As discussed above, three of the mutations in the v-Myb DNA binding domain disrupt the Cyp40 binding site, and change the transforming and transactivation properties of the protein. Although most of the other mutations have been shown to aect various biological activities of v-Myb (Dini et al., 1995) , it is not yet clear whether the alterations lead to changes in protein interactions.
Conclusions
It is likely that the Myb binding proteins described here represent just a few of the possible protein interactions that will ultimately be shown to aect cMyb or v-Myb activity. For example, there is still little information about the role of the ®rst Myb repeat (R1) or the extreme N-terminus of c-Myb, domains that are highly conserved, phosphorylated in vivo and that are deleted in the activated v-Myb proteins (for review see . Another interesting domain is the serine/ threonine/proline rich domain (labeled SPRT in Figure  2 ) that is highly conserved and involved in negative regulation, but still has no known function. Also, by focusing on c-Myb and v-Myb, this review has neglected the interactions known for Myb related proteins, which will certainly turn out to be just as varied and complicated as the ones aecting c-Myb. For example, a lymphoid-speci®c protein has been identi®ed which interacts with A-Myb (Ying et al., 1997) , and interactions between B-Myb, cyclin A and cyclin-dependent kinases have been well documented (Lane et al., 1997; Sala et al., 1997; Ziebold et al., 1997) .
Perhaps one of the most surprising features shared by all the known Myb-binding proteins, is that none were originally identi®ed by two-hybrid screening methods. In an era in which two-hybrid technology has dominated the transcription ®eld, and during which so many Myb-binding proteins have been identi®ed, this result stands out. Clearly, an unbiased two-hybrid approach to the identi®cation of Mybbinding proteins is justi®ed, and is likely to result in the identi®cation of additional, interesting modi®ers of cMyb activity.
Finally, the Myb-binding proteins discussed here can be divided into two general groups. The ®rst group, including c-Maf, C/EBPb, HSF3, Ets-1 and RARa, are DNA-binding transcription factors that cooperate with or aect c-Myb or v-Myb transcriptional activity. All of these proteins interact with the Myb DNA binding domain. This suggests that the Myb repeats may have a general ability to bind other transcription factors, or may be a specialized interaction domain. The remaining proteins, p100, Cyp40, CBP/p300, cyclins and p160/p67, aect the activity of c-Myb or v-Myb, but apparently lack any innate DNA binding activity on their own. Binding sites for these modi®ers of activity are scattered throughout the Myb protein.
There is no question that the list of Myb binding proteins described here is incomplete, and that additional proteins will be identi®ed in the near future. The keys for future experiments will be to determine how each partner protein ®ts into the biology of c-Myb and v-Myb, and whether they play important roles in the regulation of cell proliferation, dierentiation and tumorigenesis.
